全文获取类型
收费全文 | 326070篇 |
免费 | 76989篇 |
国内免费 | 8465篇 |
专业分类
耳鼻咽喉 | 6823篇 |
儿科学 | 10678篇 |
妇产科学 | 3875篇 |
基础医学 | 30058篇 |
口腔科学 | 8185篇 |
临床医学 | 50889篇 |
内科学 | 81263篇 |
皮肤病学 | 15658篇 |
神经病学 | 30251篇 |
特种医学 | 12851篇 |
外国民族医学 | 26篇 |
外科学 | 62247篇 |
综合类 | 21703篇 |
现状与发展 | 94篇 |
一般理论 | 40篇 |
预防医学 | 20435篇 |
眼科学 | 6963篇 |
药学 | 18387篇 |
82篇 | |
中国医学 | 7246篇 |
肿瘤学 | 23770篇 |
出版年
2024年 | 897篇 |
2023年 | 5736篇 |
2022年 | 3888篇 |
2021年 | 7987篇 |
2020年 | 13628篇 |
2019年 | 14964篇 |
2018年 | 17967篇 |
2017年 | 19374篇 |
2016年 | 21020篇 |
2015年 | 22690篇 |
2014年 | 30913篇 |
2013年 | 32134篇 |
2012年 | 18309篇 |
2011年 | 18936篇 |
2010年 | 25427篇 |
2009年 | 24899篇 |
2008年 | 15233篇 |
2007年 | 12591篇 |
2006年 | 14541篇 |
2005年 | 10803篇 |
2004年 | 8709篇 |
2003年 | 7766篇 |
2002年 | 6870篇 |
2001年 | 7662篇 |
2000年 | 6104篇 |
1999年 | 5059篇 |
1998年 | 4552篇 |
1997年 | 4428篇 |
1996年 | 4016篇 |
1995年 | 3772篇 |
1994年 | 2421篇 |
1993年 | 1892篇 |
1992年 | 1735篇 |
1991年 | 1721篇 |
1990年 | 1319篇 |
1989年 | 1389篇 |
1988年 | 1196篇 |
1987年 | 1012篇 |
1986年 | 1013篇 |
1985年 | 837篇 |
1984年 | 616篇 |
1983年 | 587篇 |
1982年 | 566篇 |
1981年 | 437篇 |
1980年 | 383篇 |
1979年 | 347篇 |
1978年 | 367篇 |
1977年 | 408篇 |
1975年 | 292篇 |
1972年 | 318篇 |
排序方式: 共有10000条查询结果,搜索用时 23 毫秒
11.
12.
13.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
14.
15.
16.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
17.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
18.
19.
Proteomic Profiling of Small Extracellular Vesicles Isolated from the Plasma of Vietnamese Patients with Non-Small Cell Lung Cancer Reveals Some Potential Biomarkers 下载免费PDF全文
Thao Phuong Bui Phuong Lan LeLinh Thi Tu Nguyen Le Trung ThoThai Hong Trinh 《Asian Pacific journal of cancer prevention》2022,23(6):1893-1900
Background: Considering the poor prognosis of non-small cell lung cancer (NSCLC), the objective of this study was to examine the potential of plasma-derived vesicles as a source of lung cancer-specific proteins. Extracellular vesicle (EV) cargos are specific to the source cells, hence they have the potential of being a source of cancer-specific proteins. Methods: The proteins differently expressed in cancer were determined and derived from EVs isolated from the plasma of NSCLC patients at the National Lung Hospital. To this end, purification was done using gel filtration chromatography and ultracentrifugation. In addition, nano liquid chromatography mass spectrometry (LC–MS/MS) was used for analyzing. Results: Fifty-seven EV-derived proteins related to NSCLC were highlighted in this research. Some of them have not been addressed before, such as EEF1A1 (elongation factor 1-α1), KPNB1 (Importin subunit beta 1), SRC (proto-oncogene tyrosine-protein kinase) and ACTC1 (actin, alpha cardiac muscle 1). This list was further confirmed through a comparison with ExoCarta and Vesiclepedia. Conclusion: This study is the first work to show the involvement of several novel proteins of small EV (EEF1A1, KPNB1, SRC, and ACTC1) in the progression of NSCLC. The results suggested that they could serve as novel biomarkers for non-small cell lung cancer in the future. 相似文献